Sales: $877 million
Key Personnel: Kenji Ikemori, chairman and CEO; Tsuyoshi Tatai, vice president; Yasushi Sumida, executive director general manager of Fancl Research Institute; Norihiro Shigematsu, executive director vice president of health company; Yoshihisa Hosaka, executive director vice president of beauty company and general manager of online sales division; Gen Inomata, director and Fancl International Inc. and president and CEO, boscia, LLC.
Major Products: Cosmetics and skin care products sold under the Fancl and Attenir banners. Also, Boscia, a skin care company based in California, operates as a non-consolidated subsidiary of Fancl.
New Products: Mutenka skin care.
Comments: Fancl’s total net sales increased 0.6% for the year ended March 31, 2013. The slight gain was attributed to an increase in revenue from Fancl cosmetic products, which underwent a major rebranding effort. But marketing expenses from that rebranding endeavor impacted the company’s operating income; it decreased 5.7% to about $41 million despite an increase in revenues, the company said.
Cosmetics sales for its most recent fiscal year increased 2.3%. Sales of Fancl brand cosmetics increased 2.5%, due to strong sales of Mutenka Skincare products launched in March 2012. Sales of Attenir cosmetics fell 2.5% due to lackluster results of certain campaigns, the company reported. Fancl’s nutritional supplement sales fell 1.6%.
In May, Fancl announced that it would make the transition to a holding company. Effective April 1, 2014, Fancl Corporation’s cosmetics division and health foods division will be split and incorporated as new companies—Fancl Cosmetics Corporation and Fancl Health Science Corporation, respectively. Minako Yamaoka, who joined Fancl in 1995, will head the cosmetics unit.
Attenir Corp. will remain a separate company, according to the firm.